SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 03/28/2026 at 16:00, 7 months 4 days ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Positive results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented at AAD Annual Meeting, showing progressive efficacy with Q12W dosing potential

Sanofi Phase 3 Atopic Dermatitis Amlitelimab Q12W
BRIEF

published on 03/27/2026 at 13:05, 7 months 5 days ago

Sanofi's Sarclisa SC Recommended for EU Approval

Sanofi Multiple Myeloma EU Approval Sarclisa SC On-Body Injector
BRIEF

published on 03/27/2026 at 13:05, 7 months 5 days ago

Sanofi: EU approval recommended for subcutaneous Sarclisa

Sanofi Multiple Myeloma Sarclisa CHAMP Portable Injector
PRESS RELEASE

published on 03/27/2026 at 13:00, 7 months 5 days ago

Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
Sanofi's Sarclisa subcutaneous formulation via on-body injector recommended for EU approval by CHMP for multiple myeloma treatment, offering innovative delivery. Final decision expected soon

Multiple Myeloma Sarclisa CHMP Recommendation On-Body Injector Subcutaneous Formulation
BRIEF

published on 03/24/2026 at 07:35, 7 months 9 days ago

Sanofi Releases Q1 2026 Aide-Mémoire to Support Financial Analysis

Innovation Biopharma Sanofi Financial Modeling Q1 2026 Results
BRIEF

published on 03/24/2026 at 07:35, 7 months 9 days ago

Sanofi's Q1 2026 financial guide is now online

Investors Quarterly Results Sanofi Financial Document Q1 2026
PRESS RELEASE

published on 03/24/2026 at 07:30, 7 months 9 days ago

Press release: Availability of the Q1 2026 aide-mémoire
Sanofi announces availability of Q1 2026 aide-mémoire for financial modelling purposes. Details on non-comparable items, currency impact, and share count included. Results to be published on April 23, 2026

Sanofi Results Aide-mémoire Financial Modelling Q1 2026
BRIEF

published on 03/18/2026 at 07:05, 7 months 15 days ago

Sanofi's Venglustat Earns Breakthrough Therapy Designation for Gaucher Disease Type 3

FDA Sanofi Breakthrough Therapy Venglustat Gaucher Disease
BRIEF

published on 03/18/2026 at 07:05, 7 months 15 days ago

Sanofi: Breakthrough Therapy Designation for venglustat in the United States

FDA Sanofi Venglustat Medical Discovery Gaucher's Disease
PRESS RELEASE

published on 03/18/2026 at 07:00, 7 months 15 days ago

Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
Sanofi's venglustat receives Breakthrough Therapy designation in the US for type 3 Gaucher disease, a rare lysosomal storage disorder. Positive results from the LEAP2MONO study show significant improvements in neurological symptoms

Sanofi Breakthrough Therapy Venglustat Gaucher Disease Neurological Symptoms

Published on 10/30/2026 at 23:35, 2 days 11 hours ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 11 hours ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 2 days 14 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 2 days 15 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 19 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 11/02/2026 at 10:35, 14 minutes ago

Apacer to Showcase Next-Gen Storage Solutions at electronica 2026:
Published on 11/02/2026 at 10:35, 15 minutes ago

Total Voting Rights
Published on 11/02/2026 at 10:30, 20 minutes ago

Alibaba Brings Cloud and AI to the First Youth Olympic Games in Africa
Published on 11/02/2026 at 10:30, 20 minutes ago

Ernst Russ AG sells MV “Mirror”
Published on 11/02/2026 at 09:30, 1 hour 20 minutes ago

Europe's first bond for New Space investing is open for subscription from today: European Space Bond, 8% p.a. fixed interest.

View all EQS

Published on 10/30/2026 at 23:00, 2 days 11 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 2 days 14 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 2 days 16 hours ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 22 hours ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 3 days 2 hours ago

Share buyback

View all LES ECHOS COMFI WIRE

News